BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction. On March 16, 2026, she received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock at an exercise price of $57.43 per share. The option grant vests 12/48ths on March 16, 2027, with the remaining 36/48ths vesting in equal monthly installments of 1/48th on the 16th day of each month thereafter.
On March 17, 2026, 1,245 shares of Common Stock were disposed of at $56.05 per share in a tax-withholding transaction to satisfy tax obligations, rather than an open-market sale. After these transactions, Hubbard directly held 44,790 shares of BioMarin Common Stock.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg reported routine equity compensation and related tax withholding. On March 16, 2026, he received 19,150 shares of common stock as a grant and a stock option for 45,600 shares at a $57.43 exercise price, both held directly.
The restricted stock units were granted on March 16, 2026, and the option grant vests 12/48ths on March 16, 2027 and 1/48th monthly thereafter. On March 17, 2026, 1,629 shares of common stock were disposed of at $56.05 per share to cover tax obligations, leaving him with 55,099 common shares directly owned.
BioMarin Pharmaceutical executive Charles Greg Guyer reported new equity awards and a tax-related share withholding. On March 16, 2026 he received stock options for 35,680 shares of common stock at an exercise price of $57.43 per share, vesting over four years starting March 16, 2027.
He also received a grant of 14,990 shares of common stock, described in a footnote as restricted stock units granted on March 16, 2026 with no purchase price. On March 13, 2026, 9,109 shares of common stock were withheld at $58.51 per share to cover tax obligations, which is not an open-market sale. Following these transactions and a one-share clerical correction, he directly holds 85,833 shares of common stock.
BioMarin Pharmaceutical executive George Eric Davis reported new equity awards and related tax withholding. He received a stock option for 34,690 shares of common stock at an exercise price of $57.43 per share, vesting in part on March 16, 2027 and monthly thereafter until 2036.
He also received 14,570 restricted stock units on March 16, 2026, while 7,177 shares of common stock were withheld to cover tax obligations at $58.51 per share. After these transactions, Davis directly holds 79,833 shares of common stock.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported routine equity compensation and related tax withholding. He received a stock option grant for 44,600 shares of common stock at an exercise price of $57.43 per share, vesting partly from March 16, 2027 through monthly installments until 2031. He was also granted 18,740 shares of common stock as restricted stock units with no purchase price.
To cover tax obligations on a prior vesting event, 9,945 shares of common stock were withheld at $58.51 per share, a non‑market disposition. Following these transactions, Mueller directly holds 125,431 common shares and the new option for 44,600 shares.
BioMarin Pharmaceutical CEO Alexander Hardy reported new equity awards and a routine tax withholding. On March 16, 2026, he received a grant of 89,200 stock options to buy common stock at an exercise price of $57.43 per share, expiring on March 15, 2036. The option grant vests 12/48 on March 16, 2027 and 1/48 on the 16th day of each month thereafter. He was also granted 62,440 restricted stock units on the same date, with price not applicable. On March 13, 2026, 2,941 shares of common stock were withheld at $58.51 per share to cover tax obligations. Following these transactions, Hardy directly owned 218,887 shares of BioMarin common stock.
BioMarin Pharmaceutical Inc. is halting dosing and enrollment in its Phase 2 trials of VOXZOGO for Turner syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency. This decision follows several slipped capital femoral epiphysis (SCFE) events reported in two ongoing investigator-sponsored trials using VOXZOGO in these conditions.
BioMarin states that SCFE has not been seen in its own Phase 2 trials in these indications, nor among more than 5,000 infants and children treated with VOXZOGO for achondroplasia over about 10,000 patient-years of clinical and post-marketing safety data. No SCFE cases have appeared in VOXZOGO trials for hypochondroplasia. The Phase 2 CANOPY trials of VOXZOGO will continue for children with Noonan syndrome and for most participants with idiopathic short stature without ACAN-deficiency.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer sold common shares in an open-market transaction. On March 11, 2026, he sold 16,486 shares of BioMarin common stock at a weighted average price of $60.46 per share, with individual sale prices ranging from $60.39 to $60.62. After this sale, he directly held 79,953 shares of BioMarin common stock.
BMRN Form 144 filing reporting an intended sale of Common Stock through a broker. The filing lists Fidelity Brokerage Services LLC as the broker and shows 03/11/2026 as a filing date.
The filing itemizes securities tied to compensation and ESPP with quantities and dates: 1,857 shares (restricted stock vesting on 05/04/2023), 133 shares (ESPP purchase on 10/31/2023), and 14,496 shares (restricted stock vesting on 03/15/2024).
Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.